Predictors of Treatment Response in Patients with Treatment-Resistant Depression: Outcomes of a Randomized Trial

被引:0
|
作者
Khalid, Karniza [1 ,2 ]
Ang, Wei Chern [2 ]
Nazli, Aimi Izwani Mohd. [3 ]
Jamaluddin, Ruzita [2 ,3 ]
Rizvi, Syed A. A. [4 ]
机构
[1] Minist Hlth Malaysia, Inst Med Res, Specialized Diagnost Ctr, Special Prot Unit,Natl Inst Hlth, Kuala Lumpur 50588, Malaysia
[2] Minist Hlth Malaysia, Hosp Tuanku Fauziah, Clin Res Ctr, Kangar 01000, Malaysia
[3] Hosp Tuanku Fauziah, Dept Psychiat & Mental Hlth, Minist Hlth Malaysia, Kangar 01000, Malaysia
[4] Larkin Univ, Coll Biomed Sci, Miami, FL 33169 USA
来源
PSYCHIATRY INTERNATIONAL | 2023年 / 4卷 / 03期
关键词
depression; electroconvulsive therapy; transcranial direct current stimulation; treatment outcome; logistic models;
D O I
10.3390/psychiatryint4030025
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: This report aims to compare the effectiveness between electroconvulsive therapy (ECT) and transcranial direct stimulation (tDCS) among patients with treatment-resistant depression (TRD) and the associated factors. Methods: This was a secondary data analysis of a randomized, controlled, open-label trial conducted from 1 July 2018, to 31 December 2018. The dataset of 90 patients included in the study was retrieved from Mendeley Data. Patients with TRD were randomized 1:1 into either receiving ECT or tDCS. A good treatment response was determined as an improvement from the Hamilton Depression (HAM-D) baseline score at a rate of more than or equal to 50% at the end of a 2-week intervention. A mixed-effect logistic regression was performed to explain the hierarchical data structure of predictors to successful treatment outcome. Results: The largest magnitude of change was consistently observed in the ECT treatment arm across both HAM-D score and the clinical global impression severity scale (CGI-S) scale (p < 0.001). Lower baseline HAM-D scores (OR: 0.72, 95% CI: 0.58, 0.92), lower baseline CGI-S scale (OR: 0.30, 95% CI: 0.17, 0.55), and ECT as the choice of treatment modality (OR: 14.0, 95% CI: 5.08, 38.58) independently predicted successful therapy among TRD patients, while modelling with multiple logistic regression determined that low socio-economic status (aOR: 20.01, 95% CI: 1.89, 211.47), ECT (aOR: 31.7, 95% CI: 6.32, 159.0) and a lower baseline CGI-S scale (aOR: 0.18, 95% CI: 0.06, 0.57) were significantly predictive of a positive treatment outcome among patients with TRD. Conclusions: ECT was more effective in alleviating depressive symptoms in TRD as compared to tDCS.
引用
收藏
页码:246 / 254
页数:9
相关论文
共 50 条
  • [31] Predictors of response to combined wake and light therapy in treatment-resistant inpatients with depression
    Kragh, Mette
    Larsen, Erik Roj
    Martiny, Klaus
    Moller, Dorthe Norden
    Wihlborg, Camilla Schultz
    Lindhardt, Tove
    Videbech, Poul
    [J]. CHRONOBIOLOGY INTERNATIONAL, 2018, 35 (09) : 1209 - 1220
  • [32] Attrition in treatment-resistant depression: predictors and clinical impact
    Olgiati, Paolo
    Serretti, Alessandro
    Souery, Daniel
    Kasper, Siegfried
    Kraus, Christoph
    Montgomery, Stuart
    Zohar, Joseph
    Mendlewicz, Julien
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2019, 34 (04) : 161 - 169
  • [33] Predictors of efficacy in lithium augmentation for treatment-resistant depression
    Sugawara, Hiroko
    Sakamoto, Kaoru
    Harada, Tsuyoto
    Ishigooka, Jun
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2010, 125 (1-3) : 165 - 168
  • [34] Neurocognitive Effects of Ketamine and Association with Antidepressant Response in Individuals with Treatment-Resistant Depression: A Randomized Controlled Trial
    Murrough, James W.
    Burdick, Katherine E.
    Levitch, Cara F.
    Perez, Andrew M.
    Brallier, Jess W.
    Chang, Lee C.
    Foulkes, Alexandra
    Charney, Dennis S.
    Mathew, Sanjay J.
    Iosifescu, Dan V.
    [J]. NEUROPSYCHOPHARMACOLOGY, 2015, 40 (05) : 1084 - 1090
  • [35] Neurocognitive Effects of Ketamine and Association with Antidepressant Response in Individuals with Treatment-Resistant Depression: A Randomized Controlled Trial
    James W Murrough
    Katherine E Burdick
    Cara F Levitch
    Andrew M Perez
    Jess W Brallier
    Lee C Chang
    Alexandra Foulkes
    Dennis S Charney
    Sanjay J Mathew
    Dan V Iosifescu
    [J]. Neuropsychopharmacology, 2015, 40 : 1084 - 1090
  • [36] Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease
    Bangalore, Sripal
    Fayyad, Rana
    Laskey, Rachel
    DeMicco, David A.
    Deedwania, Prakash
    Kostis, John B.
    Messerli, Franz H.
    [J]. AMERICAN JOURNAL OF MEDICINE, 2014, 127 (01): : 71 - +
  • [37] Neurocognitive Effects of Ketamine in Individuals with Treatment-resistant Depression: A Randomized Controlled Trial
    Murrough, James
    Burdick, Katherine
    Perez, Andrew
    Brallier, Jess
    Chang, Lee
    Foulkes, Alexander
    Charney, Dennis
    Mathew, Sanjay
    Iosifescu, Dan
    [J]. NEUROPSYCHOPHARMACOLOGY, 2014, 39 : S391 - S391
  • [38] Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
    Smith-Apeldoorn, Sanne Y.
    Veraart, Jolien K. E.
    Kamphuis, Jeanine
    van Asselt, Antoinette D. I.
    Touw, Daan J.
    aan Het Rot, Marije
    Schoevers, Robert A.
    [J]. BMC PSYCHIATRY, 2019, 19 (01)
  • [39] Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
    Sanne Y. Smith-Apeldoorn
    Jolien K. E. Veraart
    Jeanine Kamphuis
    Antoinette D. I. van Asselt
    Daan J. Touw
    Marije aan het Rot
    Robert A. Schoevers
    [J]. BMC Psychiatry, 19
  • [40] Response shift in self-reported depression outcomes during treatment-resistant depression
    Blanchin, Myriam
    Bulteau, Samuel
    Pere, Morgane
    Sauvaget, Anne
    Sebille, Veronique
    [J]. QUALITY OF LIFE RESEARCH, 2020, 29 (SUPPL 1) : S56 - S56